मैगज़्टर गोल्ड के साथ असीमित हो जाओ

मैगज़्टर गोल्ड के साथ असीमित हो जाओ

10,000 से अधिक पत्रिकाओं, समाचार पत्रों और प्रीमियम कहानियों तक असीमित पहुंच प्राप्त करें सिर्फ

$149.99
 
$74.99/वर्ष

कोशिश गोल्ड - मुक्त

Delivering on GLP-1 demand: A combination of device offerings and supply strategy

Express Pharma

|

December 2024

Manuela Giacon, Product Manager, Pen Injectors, Stevanato Group & Josh Gordon, Product Manager, Auto-Injectors, Stevanato Group explain why auto-injectors and pen injectors will remain at the fulcrum of GLP-1 delivery

Delivering on GLP-1 demand: A combination of device offerings and supply strategy

"It is estimated that the GLP-1 market will exceed $100 bn by 2030, driven equally by diabetes and obesity usage. In the US alone, total GLP-1 users may be as much as 30 million by 2030 - that's around 9 per cent of the overall population (1). Here at Stevanato Group we believe that today, and for the foreseeable future, auto-injectors and pen injectors will remain at the fulcrum of GLP-1 delivery. And whilst this potential blockbuster treatment presents considerable opportunities for pharma partners, there are of course challenges, specifically in terms of satisfying demand.

In this article we will review the growth in demand for GLP-1 treatments and present Stevanato Group's response to this exciting opportunity, showcasing its Alina device platform for pen injectors and the Aidaptus two-step, single-use auto-injector.

In 1986, ten years after it was first introduced by Smith Kline & French, sales of peptic ulcer treatment Tagamet surpassed the $1 billion mark, making it the first drug in history to be classified as a blockbuster (2).

Since then, the pharmaceutical industry has welcomed a host of therapies and vaccines into this revered club, with indications covering everything from cancer and COVID-19 to arthritis and atrial fibrillation. In recent times, however, much of the attention in the blockbuster category has been focused on glucagon-like peptide-1 receptor agonists (GLP-1 agonists). These drugs were originally established as treatments for managing blood-sugar levels in people with Type 2 diabetes but have experienced a recent dramatic boom in demand as treatments for obesity.

Express Pharma से और कहानियाँ

Express Pharma

Express Pharma

Flexotherm Heating Tapes & Cords

Typical Applications of Heating Tapes and Cords in Industrial Solvent Handling

time to read

1 mins

October 2025

Express Pharma

Express Pharma

DRIVING INDIA'S INNOVATION EDGE

Pharma leaders come together to highlight Bengaluru's R&D strength, tech ecosystem, and talent pool to power India Pharma Inc's shift from generics to innovation and global leadership

time to read

16 mins

October 2025

Express Pharma

Express Pharma

Al compass: Transforming pharma commercialisation

As the world evolves at a rapid pace, pharma companies are embracing smarter approaches, leveraging Al across nearly every aspect of commercialisation, from market forecasting and personalised marketing to dynamic pricing and beyond. In this article, Neha Aathavale takes the pulse of the industry to explore who is taking note and how companies are beginning to put Al into action in their commercial operations

time to read

7 mins

October 2025

Express Pharma

Express Pharma

PRIME NEO: New age doors from Gandhi Automation

Gandhi Automations presents the multi-composites, high-performance door PRIME NEO for clean environments. Complete Washable, Greater Sealing and Pressure Resistant.

time to read

1 mins

October 2025

Express Pharma

Express Pharma

Unani Medicine: At crossroads of tradition and modernity

Manufacturers, academic institutions and research councils are working together to elevate Unani medicine through clinical validation and policy alignment with international standards, finds Swati Rana

time to read

7 mins

October 2025

Express Pharma

Express Pharma

Single-Use Technologies in Biologics Manufacturing: Benefits, Challenges, and Growing Demand

The biopharmaceutical industry is increasingly adopting single-use technology (SUT) to achieve flexibility, cost efficiency, and faster time-to-market. Compared with stainless steel systems, SUT reduces capital investment, eliminates cleaning and sterilization steps, lowers contamination risk, and shortens production timelines.

time to read

1 min

October 2025

Express Pharma

Express Pharma

Sustainable packaging with Romaco and Liveo Research

Recycable blister packs

time to read

3 mins

October 2025

Express Pharma

Express Pharma

With India soon to be three times the population of the EU, it makes perfect sense to have manufacturing here

As part of Sweden's Focus Asia programme, a high-level SME delegation recently visited India to strengthen bilateral ties and explore collaborations across sectors including pharma, biotech and others. Building on the momentum of the \"Time for Sweden\" event, the visit underscored Sweden's commitment to innovation, sustainability, and co-creation with India. Among the delegation was Emil Alexander Byström, CEO of SpinChem AB, who in an interaction with Kalyani Sharma shared his insights on how advanced Swedish technologies like biocatalysis and the company's patented Rotating Bed Reactor (RBR) can accelerate India's pharma and biotech innovation journey while supporting sustainable growth.

time to read

3 mins

October 2025

Express Pharma

Express Pharma

Cell therapy's next chapter: Industry embraces in-vivo innovation

Nikhil C Bhanumathi, Principal Clinical Lead, Thermo Fisher Scientific highlights that cell therapy is entering a bold new phase in 2025 as the industry shifts from complex, lab-based ex vivo CAR-T to faster, more accessible in vivo CAR-T innovations. This approach promises to expand access, lower costs, and potentially tackle solid tumors and autoimmune diseases

time to read

4 mins

October 2025

Express Pharma

Express Pharma

Research misconduct ...can delay meaningful and reliable discoveries

Dr Gráinne McNamara, Research Integrity/Publication Ethics Manager, S. Karger AG explores how research misconduct, peer review fraud slow down pharma research. Of particular concern to India is the fact that India-based researchers constitute 5 per cent of articles in life sciences retracted between 1976-2023. India-based researchers also have one of the highest rates of retraction relative to the overall publication output. Over an email exchange with Viveka Roychowdhury, she details how publishers are now deploying AI tools, some of which contributed to the problem in the first place, to detect and avert fraudulent research submissions

time to read

6 mins

October 2025

Listen

Translate

Share

-
+

Change font size